

1 **Comparison of control and transmission of COVID-19 across epidemic waves in**
2 **Hong Kong: an observational study**

3 Bingyi Yang¹, Yun Lin¹, Weijia Xiong¹, Chang Liu¹, Huizhi Gao¹, Faith Ho¹, Jiayi Zhou¹, Ru
4 Zhang¹, Jessica Y. Wong¹, Justin K. Cheung¹, Eric H. Y. Lau^{1,2}, Tim K. Tsang¹, Jingyi Xiao¹,
5 Irene O. L. Wong¹, Mario Martín-Sánchez¹, Gabriel M. Leung^{1,2}, Benjamin J. Cowling^{1,2},
6 Peng Wu^{1,2}

7
8 **Affiliations:**

9 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
10 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
11 Special Administrative Region, China.

12 2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology
13 Park, New Territories, Hong Kong.

14
15 **Corresponding author:**

16 Ben Cowling: School of Public Health, Li Ka Shing Faculty of Medicine, The University of
17 Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong

18 Email: bcowling@hku.hk

19 Tel: +852-3917 6711

20
21 **Running head:** Burden of COVID-19 and pandemic responses

22 **Keywords:** COVID-19, control, pandemic response, interventions, impact, disease

23 burden

24 **Word count:** 269 (Abstract)

25 3,859 (Main text)

26 **ABSTRACT**

27 **Background:** Hong Kong contained COVID-19 for two years, but experienced a large
28 epidemic of Omicron BA.2 in early 2022 and endemic transmission of Omicron
29 subvariants thereafter.

30 **Methods:** We examined the use and impact of pandemic controls in Hong Kong by
31 analysing data on more than 1.7 million confirmed COVID-19 cases and characterizing
32 non-pharmaceutical and pharmaceutical interventions implemented from January 2020
33 through to 30 December 2022. We estimated the daily effective reproductive number
34 (R_t) to track changes in transmissibility and effectiveness of community-based
35 measures against infection over time. We examined the temporal changes of
36 pharmaceutical interventions, mortality rate and case-fatality risks (CFRs), particularly
37 among older adults.

38 **Findings:** Hong Kong experienced four local epidemic waves predominated by the
39 ancestral strain in 2020 and early 2021 and prevented multiple SARS-CoV-2 variants
40 from spreading in the community before 2022. Strict travel-related, case-based, and
41 community-based measures were increasingly tightened in Hong Kong over the first
42 two years of the pandemic. However, even very stringent measures were unable to
43 contain the spread of Omicron BA.2 in Hong Kong. Despite high overall vaccination
44 uptake (>70% with at least two doses), high mortality was observed during the
45 Omicron BA.2 wave due to lower vaccine coverage (42%) among adults ≥ 65 years of
46 age. Increases in antiviral usage and vaccination uptake over time through 2022 was
47 associated with decreased case fatality risks.

48 **Interpretation:** Integrated strict measures were able to reduce importation risks and
49 interrupt local transmission to contain COVID-19 transmission and disease burden
50 while awaiting vaccine development and rollout. Increasing coverage of pharmaceutical

51 interventions among high-risk groups reduced infection-related mortality and mitigated
52 the adverse health impact of the pandemic.

53 **Funding:** Health and Medical Research Fund

54

55 **Key words:** COVID-19; SARS-CoV-2; pandemic preparedness; pandemic responses;

56 public health

57

58 INTRODUCTION

59 The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 led to
60 billions of infections, and more than 17 million deaths had been recorded globally from
61 late 2019.¹ Compared to the most recent influenza pandemic in 2009-2011, significant
62 improvements have been made in pandemic responses including surveillance,
63 diagnostics, and innovation and rapid development of vaccines and antivirals.² Once
64 effective pharmaceuticals became available for SARS-CoV-2, many locations began to
65 transition away from the use of stringent non-pharmaceutical interventions (NPIs) to
66 control transmission, given the substantial social and economic costs of sustaining these
67 measures. Rapid evolution of SARS-CoV-2 resulted in the emergence of new variants,
68 including Omicron that has dominated the largest waves of global transmission.^{3,4} The
69 timing and impact of pandemic waves have varied substantially around the world.⁵⁻⁷
70 Identifying the optimal combination of pharmaceutical and non-pharmaceutical
71 measures at different points in time remains a priority not only for reflecting on the
72 response to the COVID-19 pandemic but also for preparing for the next global outbreak.

73
74 As a unique case, Hong Kong adopted a stringent containment strategy since 2020, with
75 successful control of four local epidemic waves in 2020 and the first half of 2021, and no
76 major outbreaks between April and December 2021. However, a large community
77 epidemic of Omicron beginning in January 2022 caused a large number of fatalities
78 within three months, despite the availability of COVID-19 vaccines for over a year by
79 that time, and more stringent NPIs being implemented to attempt to contain
80 transmission.^{3,8} Here, we systematically examine the progression and control of COVID-
81 19 pandemic waves in Hong Kong, focusing on locally adopted control measures and

82 their impact on transmission and burden of COVID-19, to identify critical factors in
83 response and preparedness over the course of the pandemic.

84

85 **METHODS**

86 *Sources of data*

87 We obtained demographic, clinical, and epidemiological data (situation as of 29 January
88 2023) on all laboratory-confirmed and self-reported cases between January 2020 and
89 December 2022 from the Hong Kong Department of Health and Hospital Authority of
90 Hong Kong. Cases, regardless of symptoms, were recorded as laboratory-confirmed
91 when positive by reverse transcription polymerase chain reaction (RT-PCR) tests
92 throughout the pandemic and recorded as confirmed based on self-reported positive
93 rapid antigen tests (RAT) since 26 February 2022. Confirmed COVID-19 cases were
94 classified into mild/moderate, serious, critical, and fatal according to clinical outcomes,
95 while confirmed cases with available epidemiological information were further
96 classified into imported, linked-to-imported, local, and contacts of local cases
97 (Appendix).

98

99 We classified the COVID-19 pandemic in Hong Kong into six waves by confirmation date
100 of cases. Each wave was divided into pre-peak (16-50 days before peak), peak (15 days
101 before or after peak), and post-peak periods (16-50 days after peak) to reflect the
102 trajectory, where peak was defined as the day recording the largest number of
103 confirmed cases. Waves 5 and 6 were further divided into two periods to reflect
104 changes in healthcare and predominant virus variant over the epidemic, namely 5a (31
105 Dec 2021 - 6 Feb 2022), 5b (7 Feb - 22 May 2022), 6a (23 May - 30 Sep 2022) and 6b (1
106 Oct - 31 Dec 2022). Although the Hong Kong SAR Government classified the resurgence

107 of infections in June 2022 with Omicron BA.4/5 as a continuation of the fifth wave,
108 because daily cases never declined to zero prior to the resurgence, here we refer to this
109 as the sixth wave for clarity and consistency. Our project was approved by the
110 Institutional Review Board of the University of Hong Kong/Hospital Authority Hong
111 Kong West Cluster.

112

113 ***Characterization of non-pharmaceutical interventions***

114 Information on NPIs implemented in Hong Kong was collected through the government
115 press releases and classified into travel-related, community-wide, and case-based
116 measures (details in Appendix). Travel-related measures include entrance restrictions,
117 inbound traveller testing, quarantine, and exemptions. Community-wide measures
118 include school closures, work-from-home policies, mask wearing, restrictions on group
119 gatherings and measures to reduce crowding and mixing in the population. Case-based
120 interventions refer to targeted measures related to case identification, timely isolation,
121 and tracing and quarantine of contacts.

122

123 We used contact tracing data to assess the temporal changes in local case clustering
124 patterns. A cluster was defined as at least two RT-PCR confirmed cases with contact
125 history and initiated by index local cases (Appendix).⁹ We characterized the monthly
126 distribution and density distribution of cluster size, stratified by waves.

127

128 ***Case finding and contact tracing***

129 We obtained data on COVID-19 RT-PCR tests performed in Hong Kong through various
130 testing schemes (Appendix) up to wave 5a (7 February 2022),¹⁰ including daily
131 numbers of specimens tested and test positives. The testing schemes focused on

132 different risk populations, including inbound travellers, cases and their close contacts,
133 patients in clinical settings, and persons in the general community. We describe
134 temporal changes in testing capacity and case detection proportions and compare the
135 two-week moving average of numbers of specimens collected from close contacts to
136 that from the confirmed cases. We report the distribution of the delays between illness
137 onset and case confirmation for symptomatic cases as indicators of the potential impact
138 on transmissibility of case finding and isolation across waves, stratified by type of case,
139 wave and trajectory.

140

141 ***Population behavioural responses to community-based measures***

142 To assess population behavioural responses during the COVID-19 pandemic, we
143 conducted 107 rounds of cross-sectional random digit dialling telephone surveys from
144 January 2020 to December 2022 (details in appendix).^{11,12} Participants reported on face
145 mask usage, personal hygiene, and social distancing behaviours in the week prior to
146 each survey. We calculated the rim-weighted¹¹ proportion of respondents who reported
147 specific behaviours in each survey, with binomial confidence intervals (CIs).

148

149 We compared community mobility to the pre-pandemic level (1 January 2020) using
150 transaction data on Octopus cards, which is an ubiquitous stored-value and age-
151 stratified payment method for daily public transport.¹³ Overall mobility based on all
152 card types was calculated and weighted by population age-structure. Changes in
153 community mobility were analysed, stratified by time to the peak of each epidemic
154 wave and age group. We also obtained data from the Immigration Department of Hong
155 Kong to assess changes in inbound travellers during the study period.

156

157 ***COVID-19 transmission and impact of non-pharmaceutical interventions***

158 We extended the approach described by Cori *et al.*¹⁴ to estimate the time-varying
159 effective reproductive number (R_t) for imported and local cases separately to
160 characterise the transmissibility of COVID-19 (Appendix).¹⁵ We inferred the epidemic
161 curve by infection date for R_t estimation by applying a deconvolution approach¹⁶ to
162 incubation period (mean 5.2 (SD 3.9) days for waves 1-4 and mean 3.5 (SD 2.6) days for
163 waves 5-6)^{17,18}, infectiousness relative to onset time¹⁹ and infection-to-report delay
164 from empirical data.¹²

165

166 We examined the impact of combined NPIs (“NPI package”) on reducing community
167 transmission by monitoring changes in R_t for local cases. The inclusion of individual
168 NPIs was informed by the clustering and the variance explained (Appendix). Log-linear
169 regression models were used with daily R_t as an outcome and interventions as time-
170 varying covariates across waves 1 to 5a, allowing for different initial R_t and effect of
171 work-from-home of each wave. We repeated the above analyses by dropping one wave
172 at each time to test potential changes in NPIs effects across waves. R_t was estimated for
173 defined NPI packages representing different intensities of interventions and the initial
174 condition as reflected by R_t , i.e., the initial transmissibility in each wave, in comparison
175 with the scenarios of no NPIs and applying all available NPIs. 95% CIs were estimated
176 using 1,000 bootstraps of coefficient estimates following a multivariate normal
177 distribution.

178

179 ***COVID-19 fatality and pharmaceutical interventions***

180 To characterize the changes in disease burden and severity over wave and trajectory,
181 we used the weekly mortality rate and case-fatality risk (CFR) for the overall population,

182 older adults ≥ 65 years, and unvaccinated individuals, respectively. Within each group
183 and study period, the weekly mortality rate was calculated as the weekly number of
184 COVID-19 deaths over person-times observed, while the CFR was defined as the number
185 of deaths over the total number of confirmed COVID-19 cases (details in appendix). Data
186 from 1 October 2022 onwards were excluded due to potentially reduced ascertainment
187 of COVID-19 cases after that date.

188

189 Two vaccines including the inactivated vaccine CoronaVac (Sinovac) and the mRNA
190 vaccine BNT162b2 (BioNTech/Fosun Pharma/Pfizer) were provided for free in Hong
191 Kong starting from February 2021, with third doses available for adults since November
192 2021. We collected age-specific population and daily numbers of vaccine doses
193 administered by age from the territory-wide vaccine registry to calculate the proportion
194 fully vaccinated (≥ 2 doses) among the overall population and older adults ≥ 65 years of
195 age, stratified by wave and trajectory.

196

197 Two COVID-specific oral antiviral drugs, molnupiravir (Merck) and
198 nirmatrelvir/ritonavir (Pfizer) have been authorized for use in Hong Kong since late
199 February 2022 and mid-March 2022 respectively. Drug prescriptions for individual
200 patients were used to calculate the proportion of patients who were confirmed by
201 either RT-PCR or RAT and received the antivirals in all ages and unvaccinated older
202 adults ≥ 65 years, stratified by wave and trajectory.

203

204 All analyses were conducted in R version 4.0.0 (R Foundation for Statistical Computing,
205 Vienna, Austria).

206

207 **RESULTS**

208 ***Non-pharmaceutical interventions and COVID-19 transmission***

209 Hong Kong experienced six epidemic waves from January 2020 through December 2022
210 (Figure 1, Figure S1 and Table S1), with over 2.6 million laboratory- and RAT-
211 confirmed COVID-19 cases (Table 1). Notwithstanding differential ascertainment by
212 wave, only 12,631 (0.5%) cases were confirmed during the first four epidemic waves
213 predominated by the SARS-CoV-2 ancestral strain, corresponding to 1.6 cases per 1,000
214 population. In the second half of 2021, in total there were 841 (98%) imported cases
215 but only five sporadic/index local cases reported (Table 1, S2). A superspreading event
216 associated with a case of Omicron BA.2.2 who acquired the infection in a quarantine
217 hotel initiated a large fifth wave, with a cumulative incidence of 162 cases per 1,000
218 persons during January-May 2022 (wave 5), and the incidence rates dropped by 90%
219 afterwards (Figure 1).

220

221 The estimated R_t for local infections over the epidemic waves (Figure 1B) indicated that
222 transmissibility of SARS-CoV-2 decreased following (re-)implementation of strict NPIs
223 and rose after relaxation of the measures during the first four waves. In the Omicron
224 BA.2.2 wave (wave 5), R_t remained above 1 even after increasingly stringent control
225 measures were implemented during pre-peak and peak periods (wave 5), and mostly
226 fluctuated at around 1 during the Omicron BA.4/5 wave (wave 6).

227

228 Hong Kong adopted stringent border controls to prevent importation of cases, including
229 suspending 12 out of 15 boundary control points, barring entry of non-local residents if
230 they have been to overseas places, and mandating on-arrival quarantine with RT-PCR
231 testing in designated facilities for up to 21 days (Figure 1C-D and Table S3-4). We

232 observed a significant decrease in daily passenger arrivals from over 150,000 in January
233 to below 3,000 since April 2020 (a 98% decrease from January 2020) and an increase in
234 daily COVID-19 testing for inbound travellers from 1,000 in March 2020 to 6,000
235 between July and November 2021 (Figures S2-3). As a result, the R_t for imported cases
236 was maintained well below 1 since mid-February 2020 (Figure S4) and eventually
237 became unquantifiable due to too few sporadic transmission events during the
238 following waves (Table 1).

239

240 Hong Kong implemented proactive case finding and contact tracing measures, with
241 substantially expanded laboratory testing capacity over time, leading to gradually
242 shortened onset-to-report intervals (e.g., for close contacts of local cases from a median
243 of 5 to 3 days between wave 3 and 5a) (Figures S5-7, Table S5). Quarantine of close
244 contacts were enforced in designated quarantine facilities since January 2020 and home
245 quarantine was introduced since February 28, 2022, and continued until December 28,
246 2022. Numbers of specimens collected from close contacts for testing peaked before the
247 fifth wave, but the ratio to confirmed case numbers decreased substantially compared
248 to previous waves (Figure S5), consistent with widespread community transmission. In
249 clinical settings, testing was required for all pneumonia inpatients and outpatients with
250 respiratory illness since February 2020, and expanded to all hospital admissions in May
251 2020 (Figure 1 and S5). In the community, predefined higher-risk individuals were
252 required to receive regular testing since May 2020, with an increasing contribution to
253 the tested specimens from 40% in the third wave to 88% in wave 5a.

254

255 The government closed all schools and recommended civil servants to work remotely in
256 late January 2020 (Figure 1A and Table S2-4). The work-from-home recommendation

257 was removed and re-introduced in subsequent waves, while schools re-opened with
258 restrictions when local cases were low (Figure 1). During the second wave, the
259 government instituted infection control requirements for group gatherings, restaurant
260 capacity and operating hours and other non-essential business sectors in response to
261 local case clusters associated with restaurants and bars. These measures were relaxed
262 and retightened through the following waves. A face mask mandate in all indoor and
263 outdoor public areas was issued since the third wave in mid-July 2020 and remained in
264 place throughout the remaining study period and was only ultimately relaxed in March
265 2023.

266
267 Telephone surveys conducted from late January 2020 and December 2022 (total
268 n=82,562) revealed notable behavioural changes in population response to the
269 implemented NPIs. Physical distancing behaviours were observed at high proportions
270 during waves 1-6 especially when local transmission was high (67% to 90%; Figure S8).
271 Face mask use increased to a high level in January 2020 and remained very high (over
272 98%) throughout the study period. Reduced behaviour changes and risk perceptions
273 were observed during the period between wave 4 and 5, and during wave 6 (Figures S8-
274 9). There were notable reductions in public transport transactions, with the greatest
275 reductions in wave 5 (largest reduction at 37%, 95% CI, 33% to 40%), compared to
276 previous waves (Figure S10-11). Clusters with more than 10 cases involved were less
277 frequently observed after strict community-based measurements were implemented in
278 the third wave, with a median size of 10 (IQR: 5 to 19) (Figure S12).

279
280 We included a combination of NPIs that parsimoniously reflected changes in controlling
281 local transmission in the multivariate analysis (Appendix, Figure S13; adjusted R² 67%),

282 to estimate the effects of different NPI packages. The NPI packages adopted in wave 4
283 appeared to be the strictest among all the waves (Figure 2A). The initial R_t for waves
284 1&2, 3, 4 and 5a were estimated to be 1.2 (95% CI: 1.0 to 1.5), 2.6 (95% CI: 1.9 to 3.5),
285 3.0 (95% CI: 2.3 to 3.9) and 9.3 (95% CI: 6.5 to 13.4), respectively (Figure 3B and Table
286 S6). Applying all locally implemented NPIs at the most intensive level was estimated to
287 bring R_t down to below 1 (e.g., 0.6, 95% CI: 0.4 to 0.9 for wave 3), except for wave 5a
288 (3.1, 95% CI: 1.5 to 5.9), while the analysis on the strictest wave-specific NPI packages
289 showed that only the NPI package used in wave 4 seemed sufficient to control
290 epidemics in waves 1-3, but was only marginally effective during wave 4. However,
291 none of the NPI packages from earlier waves could have sufficiently suppressed
292 Omicron transmission in wave 5 (Figure 2C).

293

294 ***Pharmaceutical interventions against COVID-19***

295 In total 13,134 COVID-19 deaths were reported throughout the six waves, among which
296 74% (n=9,676) were reported between January and May 2023 (wave 5) with a peak in
297 the overall mortality rate of 2.36 (95% CI, 2.31 to 2.41) deaths per 10,000 person-
298 weeks (Figure 3-4). Among all fatal cases recorded, 92% (n=12,073) were amongst
299 older adults ≥ 65 years of age.

300

301 Uptake of the two COVID-19 vaccines in Hong Kong gradually increased during the first
302 six months after having become available, reaching a plateau between October 2021
303 and January 2022 (Figure 3). Before wave 5, approximately 70% of the population and
304 42% of older adults ≥ 65 years received ≥ 2 doses, but fewer than 10% of the whole
305 population and fewer than one-tenth of older adults had received a third dose (Figures

306 3-4). The coverage of ≥ 2 doses of vaccine increased to 82% among adults ≥ 65 years by
307 the end of wave 6.

308

309 The two antivirals molnupiravir and nirmatrelvir/ritonavir first became available only
310 during the peak of wave 5 and were provided to 18% of the adult patients ≥ 65 y within
311 one month (Figures 3-4). The usage of antivirals increased to about 40% among adults
312 ≥ 65 y.

313

314 The CFR in infected adults ≥ 65 years decreased across epidemic waves from 13% (95%
315 CI, 11% to 16%) in wave 3 to 0.83% (95% CI, 0.76% to 0.89%) in wave 6 (Figure 4B).
316 Following availability of the antivirals, CFRs among unvaccinated adults ≥ 65 y decreased
317 from 9.4% (95% CI, 7.5% to 11.6%) pre-peak of wave 5 to 3.0% (95% CI, 2.4% to 3.8%)
318 during the peak of wave 6 (Figure 4E). We observed reduced differences in CFRs and
319 weekly mortality rate between all and vaccinated adults ≥ 65 years along with the
320 increasing vaccine uptake in this age group (Figure 4F-G).

321

322 **DISCUSSION**

323 Using detailed individual case data and territory-wide population data collected during
324 the COVID-19 pandemic in Hong Kong, we were able to systematically examine the
325 progression of epidemics from 2020-2022 in relation to local pandemic responses,
326 including implementation of both NPIs and pharmaceutical interventions over the
327 course of the pandemic.

328

329 Stringent NPIs aiming to minimize importation risks and interrupt local transmission
330 chains had been implemented in Hong Kong from early in the pandemic, and

331 successfully controlled multiple epidemic waves in the community caused by the
332 ancestral strain. These measures reduced COVID-19 mortality in a highly susceptible
333 population in the absence of effective pharmaceutical interventions through effectively
334 suppressing the spread of infection.²⁰ Nevertheless, the containment strategy relying
335 solely on NPIs may not be sustainable because of the cost and disruption of these
336 measures. Successful suppression of transmission leaves a large population susceptible
337 to infection with newly emerging, immunologically distinct viral strains, and the NPIs
338 would be less effective in preventing pre-symptomatic and superspreading
339 transmissions, and in controlling infections with a relatively higher transmissibility.^{19,21}
340 In some countries, relaxation of NPIs resulted in increased COVID-19 mortality.^{1,22}
341 Achieving high vaccination coverage in the most vulnerable groups, particularly older
342 adults, would minimize COVID-19 mortality after containment measures fail or are
343 relaxed.²³
344
345 Strict travel measures were able to minimize COVID-19 introductions into the
346 community.^{24,25} Despite over 2,000 infections in arriving travellers, only three
347 independent introductions accounted for 90% of the local cases between the second
348 and fourth waves.²⁶ The other cornerstone of the approaches to COVID-19 elimination
349 in Hong Kong was the strict isolation of all confirmed cases until viral shedding of the
350 patients reached low levels before discharge, and quarantine of close contacts identified
351 from contact tracing at designated facilities. While isolation and quarantine likely
352 reduced transmission of COVID-19, it is well recognized that many infections in the
353 community were never confirmed, and a number of community epidemics occurred
354 despite intense contact tracing and timely quarantine.¹² As a consequence, the
355 containment of COVID-19 in Hong Kong cannot be attributed to strict isolation and

356 quarantine alone, while it is clear that moderate social distancing measures were
357 necessary to contain community epidemics with the ancestral strain.

358

359 Community-based physical distancing measures were widely adopted in different parts
360 of the world early in the pandemic,⁵ and individual behaviours might have also changed
361 in response to perceived risk.²⁷ Our analysis showed that the implementation of
362 packages of physical distancing measures, including school closure, working from home
363 and suspension of large gatherings, etc., correlated with subsequent decline in the
364 effective reproductive number (Figure 2) during epidemics of the ancestral strain but
365 these declines were not sufficient to achieve containment of the more transmissible
366 Omicron subvariants. It was not possible to estimate the impact from individual
367 measures which were often implemented together.

368

369 Containment of COVID-19 in Hong Kong allowed vaccination rollout in early 2021 which
370 could provide an opportunity for a transition/exit strategy from the use of NPIs for
371 containment. Despite over 70% of the Hong Kong population being fully vaccinated by
372 the end of 2021, the vaccine uptake among adults ≥ 65 years was low particularly in
373 adults ≥ 80 years (approximately 25%) before the Omicron wave. With a high incidence
374 of infections with Omicron, there was a high mortality rate of 1,500 per 1,000,000
375 persons in 2022, the majority of deaths occurring in unvaccinated older adults.

376 Conversely, locations such as Singapore that only considered containment as a
377 temporary approach prior to reaching high vaccination coverage among vulnerable
378 groups recorded much lower mortality rates in their Omicron waves.^{5,7} If all adults ≥ 65 y
379 were fully vaccinated, a large fraction of deaths in that age group during wave 5 in Hong
380 Kong might have been prevented. The successful control of community transmission for

381 two years in Hong Kong, and the intention to continue with a containment approach
382 regardless of vaccination uptake, ²⁸ might have contributed to a lack of urgency in
383 increasing vaccination uptake among vulnerable groups,^{11,29} further exacerbating the
384 low coverage of vaccine in Hong Kong. Risk communication that address the risk
385 perception and urgency of vaccine uptake, along with convenient outreach vaccination
386 programs, could help to improve vaccine uptake in most vulnerable populations.¹¹

387

388 Planning for “living with the virus” is a challenge for many different locations with
389 different control strategies during the pandemic. Clear objectives in responses are
390 essential for selecting appropriate strategies over the course of the pandemic, and the
391 ultimate goal is always to minimize severe cases and fatalities, and to protect healthcare
392 systems from being overwhelmed. In late 2021, emerging variants such as Delta
393 showing increased immune evasion caused concerns about reduced vaccine-induced
394 protection against infection.³⁰ However, evidence suggested that COVID-19 vaccines
395 had remained highly effective in preventing severe and fatal outcomes from infections
396 with the variants,^{8,31} suggesting that vaccination would still likely be an effective way to
397 reduce the severe disease burden even if not preventing infections especially in a
398 population with passive immunity conferred by vaccines.³²⁻³⁴ While Omicron was
399 associated with milder disease and lower impact in some locations,⁴ infections may
400 have a similar intrinsic severity to the ancestral virus in persons who have not been
401 vaccinated or previously infected.³⁵ Real-time risk assessment of emerging variants
402 remains a challenge.

403

404 There are several limitations of our study. First, the investigation of health impact of
405 pandemic control measures did not take into consideration the possible negative effects

406 on economy and quality of life, and the estimates might vary based on local
407 infrastructure and cultural factors. Second, we estimated the initial transmissibility for
408 each epidemic wave, but could not attribute the estimates to viral features or
409 population immunity. However, the increased transmissibility in the fifth wave was
410 likely due to increased transmissibility and immune invasion of Omicron variant, due to
411 the low seroprevalence and vaccination acquired antibodies in previous waves.³²⁻³⁴

412

413 Experience from Hong Kong has indicated that optimal pandemic control lies in timely
414 and efficient implementation of NPIs, along with a high level of population adherence
415 before pharmaceutical interventions become available. Once vaccines or antivirals can
416 be rolled out, the rationale for continuing to apply disruptive NPIs will gradually
417 weaken. Our findings highlight the value of continuously assessing the level of
418 population immunity against severe disease in the light of viral evolution and the
419 changing availability of pharmaceutical agents. In future pandemics caused by other
420 novel respiratory pathogens, employing NPIs as an initial and temporary strategy can
421 help to contain the spread, providing time to implement more sustainable control
422 measures for high-risk individuals to minimize population mortality and impact on
423 public health.

424 **ACKNOWLEDGMENTS**

425 We thank the Department of Health and the Health Bureau (former Food and Health
426 Bureau) of the Hong Kong SAR Government for providing the data for the analysis, and
427 thank Julie Au and Chloe Chui for technical assistance.

428

429 **FUNDING**

430 This project was supported by the Health and Medical Research Fund from the Health
431 Bureau of the Hong Kong SAR Government (grant numbers COVID190118 and
432 21200212), and the Collaborative Research Scheme (Project No. C7123-20G), the
433 Theme-based Research Scheme (Project No. T11-705/21-N) and the General Research
434 Fund (Project No. 17110221) from the Research Grants Council of the Hong Kong SAR
435 Government. The telephone surveys were supported by the Health and Medical
436 Research Fund (ref: COVID19F04, COVID19F11) from the Health Bureau of the Hong
437 Kong SAR Government. The funding bodies had no role in the design of the study or in
438 the analysis and interpretation of data.

439

440 **AUTHOR CONTRIBUTIONS**

441 All authors meet the ICMJE criteria for authorship. The study was conceived by BY, GML,
442 BJC and PW. Data analyses were conducted by BY, YL, CL, HG, FH, JZ, RZ, WX and TKT.
443 BY and PW wrote the first draft of the manuscript, and all authors provided critical
444 review and revision of the text and approved the final version.

445

446 **COMPETING INTERESTS STATEMENT**

447 BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Pfizer, Roche, and
448 Sanofi Pasteur. The authors report no other potential conflicts of interest.

449 **REFERENCES**

- 450 1. World Health Organization. WHO COVID-19 Dashboard. 2020.
451 <https://covid19.who.int/> (accessed 24 October 2022).
- 452 2. Fineberg HV. Pandemic preparedness and response--lessons from the H1N1
453 influenza of 2009. *N Engl J Med* 2014; **370**(14): 1335-42.
- 454 3. Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-CoV-2
455 Omicron BA.2 Variant, Hong Kong, January-March 2022. *Emerg Infect Dis* 2022; **28**(9):
456 2022.04.07.22273595.
- 457 4. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the
458 SARS-CoV-2 omicron variant in South Africa: a data linkage study. *The Lancet* 2022;
459 **399**(10323): 437-46.
- 460 5. Sachs JD, Karim SSA, Akinin L, et al. The Lancet Commission on lessons for the
461 future from the COVID-19 pandemic. *Lancet* 2022; **400**(10359): 1224-80.
- 462 6. Sonabend R, Whittles LK, Imai N, et al. Non-pharmaceutical interventions,
463 vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling
464 study. *Lancet* 2021; **398**(10313): 1825-35.
- 465 7. De Foo C, Grépin KA, Cook AR, et al. Navigating from SARS-CoV-2 elimination to
466 endemicity in Australia, Hong Kong, New Zealand, and Singapore. *Lancet* 2021;
467 **398**(10311): 1547-51.
- 468 8. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and
469 three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-
470 based observational study. *Lancet Infect Dis* 2022.
- 471 9. Adam DC, Wu P, Wong JY, et al. Clustering and superspreading potential of SARS-
472 CoV-2 infections in Hong Kong. *Nat Med* 2020; **26**(11): 1714-9.

- 473 10. Young BR, Yang B, Wu P, et al. Residential clustering of COVID-19 cases and
474 efficiency of building-wide compulsory testing notices as a transmission control
475 measure in Hong Kong. *J Infect Dis* 2023.
- 476 11. Xiao J, Cheung JK, Wu P, Ni MY, Cowling BJ, Liao Q. Temporal changes in factors
477 associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong:
478 Serial cross-sectional surveys. *The Lancet Regional Health – Western Pacific* 2022; **23**.
- 479 12. Yang B, Tsang TK, Gao H, et al. Universal Community Nucleic Acid Testing for
480 Coronavirus Disease 2019 (COVID-19) in Hong Kong Reveals Insights Into Transmission
481 Dynamics: A Cross-Sectional and Modeling Study. *Clin Infect Dis* 2022; **75**(1): e216-e23.
- 482 13. Leung K, Wu JT, Leung GM. Real-time tracking and prediction of COVID-19
483 infection using digital proxies of population mobility and mixing. *Nature*
484 *Communications* 2021; **12**(1): 1501.
- 485 14. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to
486 estimate time-varying reproduction numbers during epidemics. *Am J Epidemiol* 2013;
487 **178**(9): 1505-12.
- 488 15. Fraser C. Estimating individual and household reproduction numbers in an
489 emerging epidemic. *PLoS One* 2007; **2**(8): e758.
- 490 16. Becker DJ, Linebarger DA. Constrained iterative deconvolution applied to
491 bearing and amplitude estimation of coherent sources. [1991] Conference Record of the
492 Twenty-Fifth Asilomar Conference on Signals, Systems & Computers; 1991 4-6 Nov.
493 1991; 1991. p. 579-82 vol.1.
- 494 17. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
495 Coronavirus-Infected Pneumonia. *N Engl J Med* 2020; **382**(13): 1199-207.

- 496 18. Manica M, De Bellis A, Guzzetta G, et al. Intrinsic generation time of the SARS-
497 CoV-2 Omicron variant: An observational study of household transmission. *Lancet Reg*
498 *Health Eur* 2022; **19**: 100446.
- 499 19. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and
500 transmissibility of COVID-19. *Nat Med* 2020; **26**(5): 672-5.
- 501 20. Pei S, Yamana TK, Kandula S, Galanti M, Shaman J. Burden and characteristics of
502 COVID-19 in the United States during 2020. *Nature* 2021; **598**(7880): 338-41.
- 503 21. Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19
504 outbreaks by isolation of cases and contacts. *Lancet Glob Health* 2020; **8**(4): e488-e96.
- 505 22. Li Y, Campbell H, Kulkarni D, et al. The temporal association of introducing and
506 lifting non-pharmaceutical interventions with the time-varying reproduction number (R)
507 of SARS-CoV-2: a modelling study across 131 countries. *Lancet Infect Dis* 2021; **21**(2):
508 193-202.
- 509 23. Xiao J, Cowling BJ, Leung GM. Transitioning from covid-19 elimination to
510 sustainable endemicity in East Asia. 2021.
511 [https://blogs.bmj.com/bmj/2021/08/11/transitioning-from-covid-19-elimination-to-](https://blogs.bmj.com/bmj/2021/08/11/transitioning-from-covid-19-elimination-to-sustainable-endemicity-in-east-asia/)
512 [sustainable-endemicity-in-east-asia/](https://blogs.bmj.com/bmj/2021/08/11/transitioning-from-covid-19-elimination-to-sustainable-endemicity-in-east-asia/) (accessed 6 May 2023 2023).
- 513 24. Yang B, Tsang TK, Wong JY, et al. The differential importation risks of COVID-19
514 from inbound travellers and the feasibility of targeted travel controls: A case study in
515 Hong Kong. *Lancet Reg Health West Pac* 2021; **13**: 100184.
- 516 25. Yang B, Sullivan SG, Du Z, Tsang TK, Cowling BJ. Effectiveness of International
517 Travel Controls for Delaying Local Outbreaks of COVID-19. *Emerg Infect Dis* 2022; **28**(1):
518 251-3.
- 519 26. Gu H, Xie R, Adam DC, et al. Genomic epidemiology of SARS-CoV-2 under an
520 elimination strategy in Hong Kong. *Nature Communications* 2022; **13**(1): 736.

- 521 27. Du Z, Wang L, Shan S, et al. Pandemic fatigue impedes mitigation of COVID-19 in
522 Hong Kong. *Proceedings of the National Academy of Sciences* 2022; **119**(48):
523 e2213313119.
- 524 28. The Economist. Why Hong Kong's 'Zero-covid' strategy could backfire? 2021.
525 [https://www.economist.com/the-economist-explains/2021/10/06/why-hong-kongs-](https://www.economist.com/the-economist-explains/2021/10/06/why-hong-kongs-zero-covid-strategy-could-backfire)
526 [zero-covid-strategy-could-backfire](https://www.economist.com/the-economist-explains/2021/10/06/why-hong-kongs-zero-covid-strategy-could-backfire) (accessed 26 May 2023 2023).
- 527 29. Yuan J, Lam WTW, Xiao J, Ni YM, Cowling BJ, Liao Q. Why do Chinese older adults
528 in Hong Kong delay or refuse COVID-19 vaccination? A qualitative study based on
529 Grounded Theory. *The Journals of Gerontology: Series B* 2022: gbac184.
- 530 30. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the
531 Omicron (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.
- 532 31. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-
533 CoV-2 Omicron and Delta variants. *Nat Med* 2022; **28**(5): 1063-71.
- 534 32. Boon SS, Wong MCS, Ng RWY, et al. Seroprevalence of Unidentified SARS-CoV-2
535 Infection in Hong Kong During 3 Pandemic Waves. *JAMA Netw Open* 2021; **4**(11):
536 e2132923.
- 537 33. Poon RW, Chan BP, Chan WM, et al. SARS-CoV-2 IgG seropositivity after the
538 severe Omicron wave of COVID-19 in Hong Kong. *Emerg Microbes Infect* 2022; **11**(1):
539 2116-9.
- 540 34. To KK, Cheng VC, Cai JP, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in
541 residents evacuated from Hubei province, China: a multicohort study. *Lancet Microbe*
542 2020; **1**(3): e111-e8.
- 543 35. Wong JY, Cheung JK, Lin Y, et al. Intrinsic and effective severity of COVID-19
544 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong.
545 *medRxiv* 2023: 2023.02.13.23285848.

546 **FIGURE LEGENDS**

547 **Figure 1.** Confirmed cases (A), transmission dynamics (B), non-pharmaceutical
548 interventions (NPIs, C), testing schemes (D), self-reported population behaviours (E),
549 and population mobility (F) across the six epidemic waves of COVID-19 in Hong Kong.
550 (A) COVID-19 cases. Coloured bars indicated cases laboratory-confirmed by RT-PCR or
551 self-reported rapid antigen test (RAT) positives, which were only available after
552 February 25, 2022. Laboratory-cases were classified into sporadic/index imported
553 (dark blue), linked-to-imported (light blue), sporadic/index local (brown) and contacts
554 of local COVID-19 cases (orange). Self-reported RAT positive cases were classified into
555 imported (green) or local (pink) cases. Pie charts shows the share of case type for the
556 first four waves. (B) Estimated effective reproduction numbers (R_t) for local
557 transmission based on identified local cases. Shaded areas in dark grey indicated the
558 estimated 95% credible intervals of R_t . (C) NPIs taken to suppress and contain the
559 Covid-19 transmission in Hong Kong by time. NPIs were classified into three target
560 groups: inbound travellers (blue), community (yellow) and case and contact tracing
561 (red). Darker shading represents more stringent measures, with details in Table S4. (D)
562 COVID-19 testing schemes by target groups and settings. Items with asterisks indicate
563 testing for individuals with respiratory illness. (E) Population behaviours related to
564 physical distancing and personal hygiene measured among the general adult population
565 across 107 cross-sectional telephone surveys, January 2020 to December 2022. Point
566 estimates (points) and 95% confidence intervals (vertical segments) were estimated by
567 each survey. (F) Percentage changes in transport transactions using Octopus cards
568 relative to 1 January 2020, weighted by age-structure of Hong Kong population in 2021.
569

570 **Figure 2.** Prediction of effective reproduction numbers (R_t) of COVID-19 associated
571 with non-pharmaceutical interventions (NPIs) taken across epidemic waves. Wave-
572 specific intercepts were used as the baseline level for each epidemic wave. **(A)** NPIs
573 packages used for model prediction: the most stringent measures used in each epidemic
574 wave, no measure, and all measures. **(B)** Wave-specific R_t (row) when no or all
575 measures (column) were implemented. **(C)** Wave-specific R_t (row) under the most
576 stringent NPIs packages (column) of each epidemic wave.

577

578 **Figure 3.** Confirmed deaths, vaccine coverage, and antiviral usages across the six
579 epidemic waves of COVID-19 in Hong Kong. **(A)** Confirmed COVID-19 deaths sorted by
580 date of confirmation. Coloured bars indicated whether the fatal cases were aged 65
581 years or above (red) or otherwise (blue). **(B)** Cumulative coverage of one, two, three or
582 four doses of CoronaVac and/or BNT162b2. **(C)** Antiviral usage among confirmed
583 COVID-19 cases aged 65 and above sorted by date of confirmation.

584

585 **Figure 4.** Disease severity and burden of COVID-19 and implementations of
586 pharmaceutical interventions taken across epidemic waves. Estimates were stratified
587 by wave and trajectory. We also calculated the estimates for all Hong Kong population
588 (overall), individuals aged 65y and above, and unvaccinated individuals of all ages
589 (unvaccinated). **(A)** Mortality rate per 1000 persons per week. **(B)** Case-fatality risk.
590 Cases were all notified cases, including PCR and RAT positives. **(C)** Coverage of
591 individuals received two or more doses of COVID-19 vaccines. Vaccine coverage among
592 both all Hong Kong (overall; light colours) and individuals aged $\geq 65y$ (dark colours)
593 were calculated. **(D)** Antiviral usage among confirmed COVID-19 cases aged 65 and
594 above. **(E)** Case-fatality risk and antiviral usage in the fifth and sixth wave. Estimates

595 were calculated for unvaccinated individuals aged ≥ 65 y. **(F)** Case-fatality risk and
596 COVID-19 vaccine coverage in the fifth and sixth wave. We calculated vaccine coverage
597 as individuals aged 65 and above and received two or more doses. Case-fatality risk was
598 calculated for all adults ≥ 65 y and fully vaccinated adults ≥ 65 y, respectively. **(G)**
599 Mortality rate and COVID-19 vaccine coverage in the fifth and sixth wave. We calculated
600 vaccine coverage as individuals aged ≥ 65 y who had received two or more doses.
601 Mortality rate was calculated for all adults ≥ 65 y and fully vaccinated adults ≥ 65 y,
602 respectively.

Table 1. Characteristics of COVID-19 cases confirmed in Hong Kong by epidemic wave.

	Wave 1&2	Wave 3	Wave 4	Post wave 4	Wave 5a	Wave 5b		Wave 6a		Wave 6b		p ¹
	(1/1/20-30/4/20)	(1/5/20-30/9/20)	(1/10/20-30/4/21)	(1/5/21-30/12/21)	(31/12/21-6/2/22)	PCR	RAT	PCR	RAT	PCR	RAT	
N	1038	4050	6682	861	2804	745787	449173	189298	365711	222148	638080	
Age group (n, %)												<0.001
0-18	108 (10.4)	374 (9.2)	591 (8.8)	87 (10.1)	437 (15.6)	62994 (8.4)	55915 (12.4)	18932 (10.0)	65650 (18.0)	14726 (6.6)	107658 (16.9)	
19-29	308 (29.7)	611 (15.1)	931 (13.9)	219 (25.4)	464 (16.5)	85369 (11.4)	61363 (13.7)	21395 (11.3)	48326 (13.2)	24416 (11.0)	76807 (12.0)	
30-44	272 (26.2)	936 (23.1)	1917 (28.7)	315 (36.6)	767 (27.4)	169209 (22.7)	126669 (28.2)	40886 (21.6)	101816 (27.8)	52147 (23.5)	171390 (26.9)	
45-64	269 (25.9)	1376 (34.0)	2132 (31.9)	203 (23.6)	836 (29.8)	263295 (35.3)	131810 (29.3)	63887 (33.7)	105726 (28.9)	78735 (35.4)	194644 (30.5)	
≥65	81 (7.8)	753 (18.6)	1111 (16.6)	37 (4.3)	296 (10.6)	157587 (21.1)	73035 (16.3)	43719 (23.1)	43959 (12.0)	51794 (23.3)	87069 (13.6)	
Missing	--	--	--	--	4 (0.1)	7333 (1.0)	381 (0.1)	479 (0.3)	234 (0.1)	330 (0.1)	512 (0.1)	
Sex (n, %)												<0.001
Male	559 (53.9)	1960 (48.4)	3134 (46.9)	452 (52.5)	1316 (46.9)	366375 (49.1)	193498 (43.1)	91853 (48.5)	164372 (44.9)	105579 (47.5)	278859 (43.7)	
Female	479 (46.1)	2090 (51.6)	3548 (53.1)	409 (47.5)	1484 (52.9)	372618 (50.0)	255512 (56.9)	97021 (51.3)	201173 (55.0)	116310 (52.4)	358752 (56.2)	
Missing	--	--	--	--	4 (0.1)	6794 (0.9)	163 (0.0)	424 (0.2)	166 (0.0)	259 (0.1)	469 (0.1)	
Case classifications (n, %)												
Sporadic/index imported	616 (59.3)	664 (16.4)	1107 (16.6)	841 (97.7)	610 (21.8)	1156 (0.2)	221 (0.05)	18886 (10.0)	2985 (0.8)	45286 (20.4)	6628 (1.0)	
Linked-to-imported	88 (8.5)	5 (0.1)	11 (0.2)	10 (1.2)	848 (30.2)	56 (0.01)	4 (0.001)	7 (0.0)	30 (0.01)	0 (0.0)	0 (0.0)	

Local	169 (16.3)	1293 (31.9)	1795 (26.9)	5 (0.6)	485 (17.3)	740658 (99.3)	448822 (99.9)	170186 (89.9)	362227 (99.0)	176862 (79.6)	631452 (99.0)	
Contact of local	165 (15.9)	2088 (51.6)	3769 (56.4)	5 (0.6)	861 (30.7)	3917 (0.5)	126 (0.03)	219 (0.04)	469 (0.1)	0 (0.0)	0 (0.0)	
Severity status (n, %)												<0.001
Severe	57 (5.5)	495 (12.2)	924 (13.8)	27 (3.1)	69 (2.5)	11978 (1.6)	1511 (0.3)	3635 (1.9)	1199 (0.3)	5753 (2.6)	2275 (0.4)	
Critical	50 (4.8)	144 (3.6)	211 (3.2)	3 (0.3)	3 (0.1)	1508 (0.2)	143 (0.0)	435 (0.2)	110 (0.0)	643 (0.3)	248 (0.0)	
Fatal	5 (0.5)	105 (2.6)	102 (1.5)	1 (0.1)	3 (0.1)	8969 (1.2)	704 (0.2)	682 (0.4)	174 (0.0)	1661 (0.7)	728 (0.1)	
Delay distribution, days (mean, sd)												
Onset to hospitalization ²	5.8 (5.4)	4.7 (4.2)	3.2 (3.0)	2.5 (4.6)	2.6 (2.3)	5.0 (7.3)	11.6(10.4)	4.5 (11.4)	6.7 (16.3)	3.7 (10.1)	8.0 (12.3)	<0.001
Onset to confirmation	6.5 (5.4)	5.2 (3.8)	4.3 (3.0)	3.7 (4.4)	2.8 (1.7)	5.5 (5.4)	2.3 (4.9)	4.6 (41.0)	4.2 (5.5)	2.7 (12.9)	4.2 (35.2)	<0.001
Onset to discharge	29.1 (13.2)	18.6 (14.2)	17.3 (15.2)	20.9 (9.9)	14.4 (4.6)	17.5(20.3)	21.5 (17.1)	11.3 (14.2)	13.0 (18.5)	10.1 (11.6)	13.1 (13.5)	<0.001
Onset to death	36.4 (54.2)	36 (79.3)	29.9 (28.6)	--	31.0 (--) ³	11.9 (9.1)	17.7 (11.4)	14.2 (7.6)	14.4 (8.7)	16.1 (29.5)	15.5 (8.6)	<0.001
Confirmation to last positive sample	18.0 (12.5)	10.7 (25.7)	9.5 (10.2)	10.4 (6.8)	8.9 (4.6)	8.0 (19.1)	5.8 (16.6)	6.9 (9.0)	6.1 (8.3)	6.5 (6.5)	6.1 (5.9)	<0.001

¹ Fisher's exact test was used for categorical variables and Kruskal-Wallis rank sum test was used for all continuous variables.



² 5,215 (10%) cases were excluded from the analysis due to the recorded date of onset later than the date of hospital admission (possibly nosocomial infection)

³ Only one case died eventually among all COVID-19 cases confirmed during Wave 5a



AStrength level None Moderate Strict

medRxiv preprint doi: <https://doi.org/10.1101/2023.06.20.23291593>; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

**B****C**